Global Non Hodgkin Lymphoma Market, By Type (B-Cell Lymphomas, T-Cell Lymphoma), Treatment Type (Chemotherapy, Targeted Therapy, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Non Hodgkin Lymphoma Market Analysis and Size
The non hodgkin lymphoma market is expected to witness significant growth during the forecast period. The global paediatric hodgkin lymphoma market is majorly driven by high prevalence of non-hodgkin lymphoma, increases in number of promising pipeline drugs, high diagnostics rate and vulnerable paediatric population. Multiple treatment landscape and family history of ovarian cancer are considered positive indicators for the demand for novel ovarian cancer drugs. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the non hodgkin lymphoma market in the forecast period 2022-2029. The expected CAGR of global non hodgkin lymphoma market is tend to be around 8.50% in the mentioned forecast period. The market was valued at USD 8.33 billion in 2021, and it would grow upto USD 16 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Non-Hodgkin lymphoma is a serious and life-threatening cancer that belongs to the group of lymphomas that is developed from the lymph nodes which are the part of the immune system. Lymph nodes has key role in fighting against the infections. In the non-hodgkin lymphoma, the lymph nodes become cancerous which could affect throughout the body. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period
Non Hodgkin Lymphoma Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (B-Cell Lymphomas, T-Cell Lymphoma), Treatment Type (Chemotherapy, Targeted Therapy, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Ireland), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (U.S.), Merck & Co., Inc. (U.S.), Allergan (Ireland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Cipla Inc. (U.S.), Abbott (U.S.), Bausch Health Companies Inc. (Canada), Lupin (India), Hikma Pharmaceuticals PLC (U.K.), Amneal Pharmaceuticals LLC. (U.S.), Seagen, Inc (U.S.), ONO Pharmaceutical Co., Ltd. (Japan)
|
|
Market Opportunities
|
|
Global Non Hodgkin Lymphoma Market Dynamics
Drivers
- Increasing Investments by Market Players
Several growth strategies such as novel product launches aid in leading market players gain a competitive edge over the other players, in the upcoming years. Collaboration between major market players and smaller players can help increase their revenue shares. The smaller market leaders will acquire investments from private investors, which in turn could help them in their long-term growth.
- Rising Demand for Oral Drugs
Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.
Opportunities
- Increase in Non-Hodgkin Lymphoma
According to the American Cancer Society, non-Hodgkin lymphoma is estimated to be around 80,470. The highest rates are seen in the age group between 80 to 84 years for females and the 85 to 89 years for males. Some of these cancers are very aggressive. The need for better clinical outcomes are required more and more to treat the patients effectively. Thus, it boosts the market growth.
- Rising Healthcare Awareness
Health awareness amongst the population are rising which results in the prediction of drugs boost the market growth. The innovative launches in medications for the treatment of ovarian cancer are expected to prompt the market simultaneously. Different researchers are investing on launching the drugs that are beneficial for the market. This creates more opportunity in the market.
Restraints/Challenges
- Lack of Skilled Professionals
Lack of trained professionals who are unaware of the knowledge of the treatment methods for this disease could curb the growth of the global non hodgkin lymphoma market over a forecast period.
- High Cost
The huge expenditure of the treatment methods surely hamper the market growth. Many a times, due to lack of appropriate payment plans and special considerations by the organizations, the patients fail to adapt these high-end treatment options which in return hampers their health. Thus, this is an important restrain that needs to be taken care of.
This non hodgkin lymphoma market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the non hodgkin lymphoma market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Non Hodgkin Lymphoma Market Scope
The non hodgkin lymphoma market is segmented on the basis of type, treatment type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- B-Cell Lymphomas
- T-Cell Lymphoma
Treatment Type
- Chemotherapy
- Targeted Therapy
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Non Hodgkin Lymphoma Market Regional Analysis/Insights
The non hodgkin lymphoma market is analysed and market size insights and trends are provided by type, treatment type, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the non hodgkin lymphoma market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to have the highest market growth due to the well-developed regulatory framework and high demand of diseases specific treatment.
Asia-Pacific dominates the market due to the rise in number of generic manufacturers in this region as well as increasing disposable income.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Non Hodgkin Lymphoma Market Share Analysis
The non hodgkin lymphoma market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to non hodgkin lymphoma market.
Key players operating in the non hodgkin lymphoma market include:
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Eli Lilly and Company (U.S.)
- Merck & Co., Inc. (U.S.)
- AbbVie Inc. (Ireland)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Cipla Inc. (U.S.)
- Abbott (U.S.)
- AbbVie Inc. (U.S.)
- Merck KGaA (Germany)
- LEO Pharma A/S (Denmark)
- Bausch Health Companies Inc. (Canada)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Hikma Pharmaceuticals PLC (U.K.)
- Amneal Pharmaceuticals LLC. (U.S.)
SKU-